1. Introduction {#sec1}
===============

Tuberculosis (TB) is one of the world\'s most important infectious causes of death worldwide. More than 90 million TB patients were reported to WHO between 1980 and 2005, most of them in Asia and sub-Saharan Africa \[[@B1]\]. Spain is one of the European countries with the highest rates of incidence and prevalence of TB \[[@B2]\].

Approximately 90%--95% of individuals infected with *Mycobacterium tuberculosis* (MTB) are able to mount an immune response that halts the progression from latent TB infection to active TB disease. This is one of the main reasons that would indicate the need to identify and treat all those with risk factors for TB disease \[[@B3], [@B4]\].

Susceptibility to TB seems to be multifactorial, and the development of active disease would probably be the result of a complex interaction between the host and pathogen influenced by environmental and genetic factors. Numerous host genes are likely to be involved in this process \[[@B5]--[@B7]\].

Mannose-binding lectin (MBL) is an acute phase protein primarily produced by the liver. One of its main roles is to activate the complement system suggesting that it is one of the most important constituents of the innate immune system \[[@B8]--[@B12]\]. The gene encoding MBL has been associated with susceptibility to TB and other infectious diseases \[[@B8], [@B13]\]. The first mutation in *MBL2*, the gene encoding MBL was found in 1991 \[[@B14]\]. Three structural mutations, affecting codons 52, 54, and 57, in the first exon of the *MBL2* gene (MBL1 is a pseudogene) have been found, and the corresponding alleles were designated D, B, and C, respectively (A is the wild-type allele for all three positions). Moreover, three polymorphisms have also been identified in the *MBL2*promoter and 5′-untranslated regions: H/L at position −550, X/Y at position −221, and P/Q at position +4 \[[@B15]\].

The effect of the three structural mutations in the *MBL2* first exon involves the impairment of MBL multimerization. This caused decreasing ligand binding and, consequently, a lack of complement activation \[[@B16]\]. In general, all these genetic variants result in a phenotype of low serum MBL levels, which influences the susceptibility to TB and the course of different diseases \[[@B13], [@B17], [@B18]\].

To date, controversial results have been reported regarding the relationship between structural genetic variants or polymorphisms of the *MBL2* gene and an increased risk of TB in different populations \[[@B19]--[@B30]\]. Several studies have found a significant association between the frequency of structural alleles or promoter polymorphisms and serum MBL levels with susceptibility to TB \[[@B20], [@B23], [@B24], [@B26]--[@B30]\] while others did not find any significant association \[[@B19], [@B21], [@B25]\]. Recently a meta-analysis of 17 human trials considering the effect of *MBL2* genotype and/or MBL levels and TB infection did not found significant association between *MBL2* genotype and pulmonary TB infection \[[@B22]\]. The majority of studies analysed did not report neither the *MBL2* haplotype nor the promoter polymorphisms. The aim of our study was to analyse if gene variants, promoter polymorphisms, haplotypes, or diplotypes could contribute to increase the risk of active pulmonary TB (PTB) in a human immunodeficiency virus negative genetically homogeneous population (Cantabria, Northern Spain), containing newly diagnosed patients with active disease.

2. Material and Methods {#sec2}
=======================

2.1. Study Population {#sec2.1}
---------------------

To investigate the possible association between *MBL2* polymorphisms and PTB infection in our population, we recruited a total of 107 active PTB patients and 441 randomly selected healthy blood donors from Cantabria (northern Spain). All of them were HIV negative.

The study was conducted at a 1,200-bed community and teaching hospital. Both, blood donors (mean age, 48 years; range, 18--65 years; male/female ratio, 1.3) and PTB patients (mean age, 56 years; range, 23--76 years; male/female ratio, 1.5) were of Caucasian background. The PTB patients group was selected from patients admitted to the Infectious Unit and the Department of Respiratory Medicine (Hospital Universitario Marqués de Valdecilla) from 2008 to 2011 and who fulfilled clinical, radiological, and bacteriological criteria of active PTB according the standards for the diagnosis and classification of TB developed by the American Thoracic Society and the Centers for Disease Control and Prevention (<http://www.cdc.gov/mmwr/>). Diagnosis of PTB was made clinically and by X-rays and confirmed by bacteriological (microscopy and culture) procedures. We excluded patients with extrapulmonary TB due to dissemination and subsequent involvement of single or multiple nonpulmonary sites. In the same way, we excluded patients with autoimmune or neoplastic diseases, chronic renal failure, transplant individuals, and patients suffering from alcoholism or drug abuse. Controls had neither previous history of TB nor contact with infected patients. Furthermore, we ruled out the presence of active or latent TB in the control group by performing an interferon-gamma release assay (Quantiferon TB Gold, Cellestis Ltd., Carnegie, Victoria, Australia). All the procedures used in the study conformed to the principles outlined in the Declaration of Helsinki. Informed consent was obtained and data anonymously recorded. The study protocol was accepted and approved by the Research Ethics Board of the Hospital.

2.2. DNA Extraction and Amplification of Genomic DNA for **MBL2** Genotyping {#sec2.2}
----------------------------------------------------------------------------

Blood was collected in EDTA-stabilized tubes in compliance with approved protocols from our institution. Genomic DNA from patients and controls was extracted from peripheral blood by using the Maxwell 16 Genomic DNA Purification system. For *MBL2* gene amplification and genotyping, we used the INNO-LiPA *MBL2* (Innogenetics Diagnóstica Iberia S.L.U, Barcelona, Spain), following the manufacturer\'s instructions. The INNO-LIPA *MBL2* is a line probe assay, designed for genotyping the 6 variations in the human *MBL2* gene (−550G \> C, −221G \> C, +4C \> T, R52C, G54D, and G57E) which leads to analyse the seven common haplotypes and the 28 possible resulting diplotypes.

3. Statistical Analysis {#sec3}
=======================

Frequencies of alleles and diplotypes of patients and healthy controls were estimated by direct counting. Alleles and genotypic (dyplotypes) frequencies were compared by *χ* ^2^ test or the Fisher\'s exact test when necessary. *P* values with Yates correction and odds ratio (OR) with 95% confidence intervals (CI) were calculated using SPSS version 12.0 (SPSS Inc, Chicago, IL, USA). *P* \< 0.05 was considered statistically significant. Hardy-Weinberg equilibrium (HWE) was tested in patients and controls for all the analysed parameters. Bonferroni correction for multiple comparisons was applied in order to avoid false positive results.

For haplotype analysis, frequencies and linkage disequilibrium were calculated trough the expectation maximization algorithm using the SNPStats web-based tool (<http://bioinfo.iconcologia.net/SNPstats/>). To determine the linkage disequilibrium between pairs of alleles, we calculated the D′ statistic. Comparisons between patients and controls were performed by *χ* ^2^ test or the Fisher\'s exact test considering each haplotype like an allele.

Statistical power was calculated by using the PS power and sample size calculation software version 3.0, (<http://biostat.mc.vanderbilt.edu/PowerSampleSize>).

4. Results and Discussion {#sec4}
=========================

4.1. *MBL2* Structural Variants, Promoter Polymorphisms, and Genotypes {#sec4.1}
----------------------------------------------------------------------

Frequencies of *MBL2* alleles are shown in [Table 1](#tab1){ref-type="table"}. All the structural genetic variants and the promoter polymorphisms were within the range of HWE. The average heterozygosity in the control group was 0.88 when the seven alleles of the *MBL2* gene were analysed, being this frequency higher than others previously reported in different populations \[[@B30]\].

There was no significant difference in the frequencies of the different promoter polymorphisms. Regarding the structural variants, only D allele was significantly more frequent in controls (*P* = 0.014, OR 0.33, and CI 95% 0.13--0.84), but this significance disappeared after Bonferroni correction.

[Table 2](#tab2){ref-type="table"} shows the frequency of the *MBL2* haplotypes in controls and PTB patients from Cantabria compared with other previously reported populations. As with D structural variant, HYPD showed the same significant difference between PTB patients and controls which disappeared after Bonferroni correction. All the promoter polymorphisms and structural variants conforming the different haplotypes were in linkage disequilibrium (*P* \< 2*e* − 16).

4.2. *MBL2* Complete Genotypes (Diplotypes) in PTB Patients and Healthy Controls {#sec4.2}
--------------------------------------------------------------------------------

The frequencies of all the possible combinations of the seven haplotypes that appeared in both groups are shown in [Table 3](#tab3){ref-type="table"}. No significant differences were found in any of the complete diplotypes between PTB patients and healthy controls.

All seven haplotypes were present in both groups following the same order of frequency in them, giving rise to 22 different *MBL2* diplotypes in our subjects. Eighteen of these diplotypes were present in both groups, 5 in either the PTB patients or the control group, and six diplotypes were not observed in any of the groups.

HYPA was the most frequent haplotype, followed by LYQA, LXPA, LYPB, LYPA, HYPD, and LYQC, respectively. When we regrouped the 22 observed diplotypes in all the possible genotypic combinations (structural-structural, structural-polymorphism, and polymorphism-polymorphism), we did not find any significant difference (data not shown).

5. Discussion {#sec5}
=============

Innate immunity is one of the most important barriers against invading pathogens. The complement system gets activated when these microorganisms are detected, resulting in biochemical pathways that lead to the destruction of the infectious agent. One of these pathways that make up the complement system is the lectin pathway in which MBL plays the main role. MBL protein is therefore important, especially in first-line defense against invading pathogens. It has been reported that low levels of circulating MBL may predispose against infectious diseases \[[@B8], [@B31], [@B32]\].

Structural variants are found at the coding regions of the *MBL2* gene that lead to low or near absent serum MBL levels in heterozygosis and homozygosis, respectively. Low-serum levels of MBL are associated with defects in opsonization, resulting in recurrent infections mainly during infancy \[[@B31]\]. Due to a strong linkage disequilibrium between the polymorphisms present in the promotor and the structural variants in exon 1 of the human *MBL2* gene, only seven common haplotypes have been described (HYPA, LYPA, LXPA, LYQA, HYPD, LYPB, and LYQC) which give rise to 28 possible haplotype combinations. The frequencies of the seven haplotypes vary considerably between populations \[[@B17], [@B18]\]. Among haplotypes carrying the wild-type A allele, HYPA results in the production of higher amounts of MBL, whereas LXPA is associated with lower serum MBL levels.

Several groups have studied *MBL2* genetic variants and PTB, suggesting a partial protective effect of heterozygosity for *MBL2*variant alleles against PTB \[[@B33]--[@B35]\], whereas others have pointed toward a susceptibility to PTB for homozygous carriers of *MBL2* variant alleles \[[@B36]\].

Previous studies have found controversial results, at least at a genetic level. Some authors have reported a lower frequency of allele B in Afro-Americans, but not in Caucasian or in the so-called "Hispanic" TB patients \[[@B28]\]. However, other reports have not found any significant differences in the frequency of structural *MBL2*alleles between PTB Caucasian patients and control subjects. Nevertheless, when they included the promoter polymorphisms according to high serum MBL levels (*YA/YA*, *YA/XA*, *XA/XA*, and *YA/O*), low MBL levels (*XA/O*), and deficient MBL individuals (*O/O*),a significant difference in diplotype frequency was revealed \[[@B25], [@B27], [@B29]\]. Finally, another study has found a significantly increased frequency of *O/O* diplotype of structural polymorphism and of *Y/Y* diplotype of promoter polymorphisms in HIV-TB+ patients compared with controls \[[@B24]\].

In the present study, we have investigated whether structural variations or promoter polymorphisms in the *MBL2* gene considering them individually of regrouped might be associated with PTB in Northern Spain. Our results after statistical correction show that there is no differences neither in the frequencies of polymorphisms in the promoter and 5′-untranslated region nor in the structural variants of the exon 1 of the *MBL2* gene between PTB patients and control subjects when we considered them individually.

Lack of concordance of our results and those from other studies, specifically another Spanish report that studied *MBL2* gene variants in the population from Canary Islands, \[[@B27]\] could be explained, at least, by the genetic characteristics of both pathogens and hosts. There are, consequently, two possibilities to understand these differences among insular and peninsular Spaniards.

First of all, it should be considered the different ethnic background of geographically apart populations \[[@B37]--[@B40]\]. Genetic studies have demonstrated that an aboriginal African background still persists in inhabitants from Canary Islands. Estimates of genetic contribution to the Canary Islanders from their putative parental populations based on mtDNA and other genetic markers are 43% Berbers, 35% Peninsular Spaniards, and 21% Guineans (being the Spanish nuclear contribution due to males and practically all the Berber and Guinean due to females). On the other hand, Cantabrians, at the North of the Iberian Peninsula, appear as a semi-isolated result of an ancient indigenous substrate more or less mixed with more recent immigrants. This population seems to be a genetically well-differentiated community, as deduced from uniparental and autosomal markers, perhaps to a higher level than their neighbours, the Basques, the most reputed European isolate on linguistic grounds \[[@B41]--[@B43]\].

Secondly, another explanation could be due to the genetic background within *M. tuberculosis* because variability among different strains of *M. tuberculosis* in their surface, oligosaccharides, might have led to differences in the MBL levels associated with resistance or susceptibility against PTB \[[@B27], [@B44], [@B45]\]. Consequently, when geographic variation in pathogen polymorphism is superimposed on host genetic heterogeneity, considerable variation may occur in detectable allelic association \[[@B5]\]. These factors could explain our findings in the analysed Northern Spanish population.

6. Conclusion {#sec6}
=============

The results obtained in our study show a significant higher prevalence of *MBL2* D allele and HYPD haplotype in controls than in PTB patients (6.7% versus 2.3%, *P* = 0.014, OR 0.33, and CI 95% 0.13--0.84).

Although after statistical correction, the significance disappeared; this trend of the *P* values to significance could indicate a role of D allele and HYPD haplotype in conferring protection against PTB. For this reason, we cannot argue that *MBL2* D allele or HYPD haplotype would act as a factor of resistance to PTB, and susceptibility to this disease would probably be determined by other environmental and genetic factors, at least in our population \[[@B20], [@B46]--[@B50]\].
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###### 

Allelic frequencies of *MBL2* structural variants and promoter polymorphisms in healthy controls and patients with pulmonary tuberculosis.

                   Structural variants   Promoter polymorphisms                                                                      
  ---------------- --------------------- ------------------------ ------- ------------------ ------- ------- ------- ------- ------- -------
  Controls                                                                                                                            
   (*n* = 441)     0.782                 0.143                    0.008   **0.067**          0.655   0.345   0.760   0.240   0.815   0.195
  PTB Patients                                                                                                                        
   (*n* = 107)     0.836                 0.131                    0.009   **0.023**          0.678   0.322   0.776   0.224   0.757   0.243
  *P* value^a,b^                                                          **0.014**                                                   
  OR                                                                      **0.33**                                                    
  (95% CI)                                                                **(0.13--0.84)**                                            

^a^Only D variant showed significant differences between the two groups. The rest of structural and promoter alleles did not show significant differences.

^b^The study had 74% power for detecting an odds ratio (OR) ≥ 2.

###### 

Frequency of *MBL2* haplotypes in controls and PTB patients from Cantabria compared with other previously reported populations.

  Haplotype   Population                                                                          
  ----------- ------------ -------------- ------ ------ ------ ------ ------ ------ ------ ------ -------
  HYPA        0.28         0.30           0.24   0.81   0.31   0.44   0.08   0.06   0.54   0.38   0.75
  LYQA        0.23         0.23           0.22   0      0.19   0.16   0.25   0.27   0.01   0      0.01
  LYPA        0.07         0.08           0.08   0.04   0.04   0.07   0.13   0.30   0.02   0.08   0.23
  LXPA        0.21         0.23           0.19   0.03   0.26   0.11   0.24   0.13   0.01   0.04   0.01
  LYPB        0.14         0.13           0.17   0.12   0.11   0.22   0.02   0      0.42   0.46   0
  LYQC        0.01         0.01           0.03   0      0.03   0      0.24   0.24   0      0.04   0
  HYPD        0.07         **0.02** ^a^   0.07   0      0.06   0      0.04   0      0      0      0.003
                                                                                                  
  H^b^        0.81         0.82           0.82   0.33   0.79   0.72   0.81   0.76   0.54   0.66   0.39

Controls, healthy population from Cantabria, PTB, patients with pulmonary tuberculosis from Cantabria, CAN, and Gran Canaria p; ESK, Eskimo; DAN, Danish; JAP, Japanese; KEN, Kenya; MOZ, Mozambique; CHIR, Chiriguano (South America); MAP, Mapuche (South America); WAR, Warlpiri (Australia) populations.

^a^ *P* value 0.014 (OR 0.33 and 95% CI 0.13--0.84): frequency of HYPD haplotype in PTB patients versus control subjects from Cantabria.

^b^Average heterozygosity of the seven alleles when they were considered together.

###### 

Frequencies of complete diplotypes in Spanish PTB patients and controls.

  ------------------------------------------------------------------------------------
  *MBL2*diplotypes\*   PTB patients\   Controls\    *P* value   OR     (95% CI)
                       *n* (%)         *n* (%)                         
  -------------------- --------------- ------------ ----------- ------ ---------------
  LYQA/HYPA            17 (15.9)       54 (12.24)   0.40        1.35   (0.75--2.45)

  LYQA/LYPB            10 (9.3)        29 (6.58)    0.43        1.46   (0.69--3.11)

  LYQA/LYPA            6 (5.6)         19 (4.31)    0.60        1.32   (0.51--3.39)

  LYQA/LYQA            3 (2.8)         19 (4.31)    0.59        0.64   (0.19--2.20)

  LYQA/HYPD            1 (0.9)         10 (2.27)    0.70        0.41   (0.05--3.21)

  LYQA/LYQC            0 (0)           2 (0.45)     1.0         NA     NA

  LYQC/HYPD            0 (0)           1 (0.23)     1.0         NA     NA

  LXPA/HYPA            15 (14.0)       45 (10.20)   0.34        1.43   (0.77--2.69)

  LXPA/LYQA            10 (9.3)        53 (12.02)   0.54        0.75   (0.37--1.54)

  LXPA/LXPA            7 (6.5)         14 (3.17)    0.15        2.14   (0.84--5.43)

  LXPA/LYPB            4 (3.7)         31 (7.03)    0.30        0.51   (0.18--1.49)

  LXPA/HYPD            3 (2.8)         13 (2.95)    1.0         0.95   (0.27--3.39)

  LXPA/LYPA            1 (0.9)         10 (2.27)    0.70        0.41   (0.05--3.21)

  LXPA/LYQC            1 (0.9)         2 (0.45)     0.48        2.07   (0.19--23.05)

  HYPA/HYPA            10 (9.3)        38 (8.62)    0.96        1.09   (0.53--2.27)

  LYPB/HYPA            8 (7.5)         38 (8.62)    0.88        0.86   (0.39--1.89)

  LYPB/LYPB            1 (0.9)         7 (1.59)     1.0         0.58   (0.07--4.81)

  LYPB/LYQC            1 (0.9)         1 (0.23)     0.35        4.15   (0.26--66.90)

  LYPB/HYPD            0 (0)           9 (2.04)     0.22        NA     NA

  LYPA/HYPA            4 (3.7)         18 (4.08)    1.0         0.91   (1.30--2.75)

  LYPA/LYPB            3 (2.8)         4 (0.91)     0.14        3.15   (0.69--14.30)

  LYPA/LYPA            1 (0.9)         2 (0.45)     0.48        2.07   (0.19--23.05)

  LYPA/LYQC            0 (0)           1 (0.23)     1.0         NA     NA

  LYPA/HYPD            1 (0.9)         2 (0.45)     0.48        2.07   (0.19--23.05)

  HYPD/HYPA            0 (0)           14 (3.17)    0.08        NA     NA

  HYPD/HYPD            0 (0)           5 (1.13)     0.59        NA     NA
  ------------------------------------------------------------------------------------

^∗^Frequencies of the rest of combined diplotypes (LYQC/HYPA, LYQC/LYQC) were 0 in both groups.
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